Sagent Pharmaceuticals has launched Nafcillin for Injection, USP in two vial presentations and one pharmacy bulk package bottle, which are preservative-free and latex-free.
Nafcillin had hit nearly $62m sales for 12 months ending September 2012 in US, according to IMS.
The injection comes with the company's PreventIV Measures packaging and labeling to reduce medication errors.
Nafcillin for Injection, USP is a semisynthetic penicillin to cure infections caused by penicillinase-producing staphylococci, which have shown susceptibility to the drug.
It may also be used as a therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results.
Source:
http://drugdelivery.pharmaceutical-business-review.com/news/sagent-pharmaceuticals-launches-nafcillin-for-injection-031212
